In regulated environments, validation refers to the documented evidence that a process, procedure, or computerized system reliably meets defined requirements. In clinical trials, validation is particularly relevant to ensure data integrity, patient safety, and compliance with Good Clinical Practice.
What is validated in clinical trials?
In practice, the term is used broadly. Typically, a distinction is made between process validation (e.g., laboratory workflows or manufacturing processes), method validation (e.g., bioanalytics), and computerized system validation (Computerized System Validation, CSV). For sponsors and CROs, CSV is particularly important because many core functions run via IT systems, such as electronic data capture, randomization, ePRO, or electronic archiving in the Trial Master File.
- Systems: EDC, eTMF, safety databases, eConsent platforms, CTMS.
- Processes: data cleaning, query management, coding (e.g., MedDRA), SAE reporting.
- Interfaces: data transfers between systems (e.g., lab to EDC) and their plausibility checks.
Validation is not just a one-time test, but a lifecycle: defining requirements, testing, documenting, controlling changes, and regularly checking whether the system remains “fit for purpose”.
Lifecycle and typical documents
In GxP environments, validation follows a structured approach. Common components include a User Requirements Specification (URS), risk assessment, validation plan, test scripts, and a final report. In projects involving multiple service providers, it must also be clearly defined who performs which validation activities and how evidence is exchanged between sponsor, vendor, and CRO. Especially with software as a service, release cycles and change control are frequent bottlenecks.
- Requirements: URS and specifications define what the system must be able to do.
- Risk-based approach: Critical functions are tested more extensively (ALCOA principles, data flow analysis).
- Testing: Installation Qualification, Operational Qualification, and, if applicable, Performance Qualification, including negative testing.
- Release: validation report, formal decision to use, and documentation in the Quality Management System.
Equally important is the interaction with Standard Operating Procedures, training records, and a traceable audit trail. Without these fundamentals, a “test passed” has little regulatory value because traceability and responsibilities are missing.
Validation vs. verification and “fit for purpose”
In day-to-day practice, validation is sometimes confused with verification. Verification checks whether a system or process is “built correctly” (i.e., meets the specification). Validation demonstrates whether it is “fit for purpose” and functions reliably in real-world use. This distinction is particularly important for study data: a formally correct installation can still be unsuitable if workflows do not fit the study or the user interface encourages use errors.
Another practical point is vendor qualification. When a sponsor or CRO accesses an externally operated system, vendor audits, service level agreements, and transparency regarding release content play a major role. Without controlled change management, a system update in the middle of a study can lead to unplanned deviations that then have to be documented as a system incident.
Risk-based validation and data integrity
From a regulatory perspective, a risk-based approach is increasingly expected: not every function requires the same level of testing, but the decision logic must be documented. Critical aspects include, for example, access and role concepts, audit trail, data exports for biostatistics, and backup and restore processes. A common mistake is that export formats are not tested against the URS, which can delay subsequent analyses.
Integration into study documentation is also often underestimated. Validation evidence generally belongs in the Trial Master File or must at least be clearly referenced. During inspections, questions often go beyond test protocols to include how changes were controlled, incidents assessed, and users trained. A pragmatic solution is a validation “evidence package” that brings together URS, risk assessment, tests, deviations, and release in a traceable structure.
Relevance for clinical trials
Validation directly protects the interpretability of a study. For example, if an EDC system performs calculations incorrectly, audit trails are incomplete, or export formats are inconsistent, this can jeopardize data analysis and thus the primary endpoint. From an operational perspective, validation is also a key element in reducing audit and inspection risk, because inspectors can understand why a system was used and how its suitability was demonstrated.
In Germany and the EU, the separation of responsibilities is also central: the sponsor remains responsible even if tasks are outsourced to CROs or IT service providers. Validation evidence must therefore be available and be able to be provided promptly when needed. In many projects, it is helpful to create a validation roadmap early on that aligns study start-up, vendor setup, and data management milestones. This helps avoid situations where a system is technically ready but has not yet been formally released for productive study operations.
Frequently Asked Questions (FAQ)
Does every IT system in a clinical trial need to be validated?
Systems that generate, process, or store GxP-relevant data should be validated based on risk. The scope depends on criticality, complexity, and the ability to detect and correct errors.
What is the difference between CSV and general IT quality assurance?
CSV is formally regulated and focuses on data integrity, traceability (audit trail), and controlled changes. General IT testing can be part of it, but it does not replace documented validation.
How often is revalidation required?
Revalidation is typically required for significant changes (change control), e.g., new releases, new workflows, or interfaces. In addition, periodic reviews are advisable to demonstrate ongoing fitness for purpose.
Regulatory References
- ICH E6(R3) Good Clinical Practice: expectation of risk-based quality management, including appropriate systems and traceable documentation.
- EU Regulation (EU) No 536/2014 (Clinical Trials Regulation): requirements for reliable conduct and documentation of clinical trials in the EU.
- EMA Guideline on computerised systems and electronic data in clinical trials: guidance on the use and control of computerized systems and electronic data in clinical trials.